NewAmsterdam Pharma Co N.V. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
NewAmsterdam Pharma filed an 8-K on August 14, 2026 (for period ending August 10, 2026) disclosing Item 5.02 regarding departure of director(s) or officer(s) and/or appointment of officer(s) with compensatory arrangements. The filing document exists but specific names, titles, departure dates, compensation amounts, and replacement details are not provided in the header text extracted.
Why this rating
Leadership changes are moderate-significance events. Without specific names, roles, or compensation details, cannot assess materiality. Routine 8-K disclosure without quantified financial impact or strategic context.
Extracted items
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.